Vimarsana
Biggest News Aggregation in the World

Cell Bioengines News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Cell Bioengines. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Cell Bioengines Today - Breaking & Trending Today

SOSV-backed Biotech Firm Cell BioEngines Decides New York - Vimarsana News

SOSV-backed Biotech Firm Cell BioEngines Decides New York

Cell BioEngines, Inc., founded by visionary Dr. Ajay Vishwakarma aiming to turn cancer into a curable disease announced today that the SOSV-backed company...

Cell BioEngines Enters Agreement with Miltenyi Bioindustry - Vimarsana News

Cell BioEngines Enters Agreement with Miltenyi Bioindustry

Cell BioEngines to Leverage Miltenyi’s Expertise and Proven Platforms to Develop and Manufacture Hematopoietic Stem Cell Transplantation (HSCT) Product...

Cell BioEngines Licenses Patent for Allogeneic - Vimarsana News

Cell BioEngines Licenses Patent for Allogeneic

Small molecule-mediated expansion of engraftable cord-blood derived hematopoietic stem cells (HSC) to address donor availability for allogenic...

Cell BioEngines Licenses Patent for Allogeneic Hematopoietic Cell Transplantation in Oncology - Vimarsana News

Cell BioEngines Licenses Patent for Allogeneic Hematopoietic Cell Transplantation in Oncology

BOSTON and NEW YORK, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Cell BioEngines, Inc. is strengthening its Intellectual Property portfolio with a patent licensed from the Icahn School of Medicine at

Cell BioEngines Enters into an Exclusive Worldwide Agreement to Develop and Commercialize Potent Immune Cell States to Cure Cancer - Vimarsana News

Cell BioEngines Enters into an Exclusive Worldwide Agreement to Develop and Commercialize Potent Immune Cell States to Cure Cancer

BOSTON and NEW YORK, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Cell BioEngines Inc. (the “Company”), a cell and gene therapy company focused on developing an allogenic cell-based product for solid tumors, today announced that it has entered into ...